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Abstract
Nifedipine is widely used as a calcium channel blocker (CCB) to treat angina and
hypertension,but it is controversial with respect the risk of stimulation of cancers. In
this study, we demonstrated that nifedipine promoted the proliferation and migration
of breast cancer cells both invivo and invitro. However, verapamil, another calcium
channel blocker, didn’t exert the similar effects. Nifedipine and high concentration
KCl failed to alter the [Ca2+]i in MDA-MB-231 cells, suggesting that such nifedipine
effect was not related with calcium channel. Moreover, nifedipine decreased
miRNA-524-5p, resulting in the up-regulation of brain protein I3 (BRI3). Erk pathway
was consequently activated and led to the proliferation and migration of breast
cancer cells. Silencing BRI3 reversed the promoting effect of nifedipine on the
breast cancer. In a summary, nifedipine stimulated the proliferation and migration of
breast cancer cells via the axis of miRNA-524-5p-BRI3–Erk pathway independently
of its calcium channel-blocking activity. Our findings highlight that nifedipine but not
verapamil is conducive for breast cancer growth and metastasis, urging that the
caution should be taken in clinic to prescribe nifedipine to women who suffering
both hypertension and breast cancer, and hypertension with a tendency in breast
cancers.
Introduction
Breast cancer is one of the most prevalent human cancers worldwide and accounts
for 26% of all cancers (excluding basal and squamous cell skin cancers) in women
according to the Cancer Statistics of 2008 [1]. Men also suffer breast cancer
commonly with poorer outcomes due to delays in diagnosis. Accumulated results
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have revealed that the genetic mutations and individual living environment
together contribute to the incidence of the breast cancer [2–4].
Calcium channel blockers (CCBs) disrupting the movement of calcium through
calcium channels, include dihydropyridine, phenylalkylamine and benzothiaze-
pine. Three kinds of reagents display different molecular structures and bind
separately with receptor sites located in or near the calcium channel [5]. Among
them, nifedipine (also named Adalat, Nifediac, Nifedical or Procardia) is
commonly used in the treatment of angina and hypertension.
Several epigenetic studies have implicated that CCBs might be involved in
cancer stimulation, but the risk of CCBs is controversial [6–9]. CCBs facilitated
the division of cells with malignant potential, thus they increased the risk of
cancers especially the breast cancer [10]. In a prospective cohort study, 451 out of
5052 people aged about 71 years had taken CCBs for four years and the hazard
ratio for cancer associated with CCBs compared with not taking CCBs was 1.72
[11]. Fitzpatrick and colleagues chose 3198 women aged over 65 years from 4
different places. They found that the elevated risk of breast carcinoma was
associated with use of CCBs and the hazard ratio was 2.57 [12]. Additional studies
consistently showed CCBs and certain diuretics increased the risk of breast
carcinoma among older women [13]. Clinic observation on the complication of
nifedipine commonly led to mental symptoms and male breast hypertrophy.
However, there are other studies showing that CCBs had no relation with cancers
[11, 14–16]. Besides these reports, amlodipine, diltiazem and verapamil were even
found to inhibit the growth of breast cancer in themodel of nude mice [17] as well
as the meningioma growth [18].
According to the statistics, about 45% of hypertension patients are women.
Dihydropyridine e.g. nifedipine accounts for 1/10 of compounds which are daily
used in the clinic treatment of hypertension and associated cardiac diseases. It is
therefore critical to understand whether CCBs can promote breast cancers and
what is the mechanism underlining this cancinoma provocation. In this study, we
found and confirmed that nifedipine, but not verapamil, could promote breast
cancer both invivo and invitro. Nifedipine decreased miRNA-524-5p, resulting in
the up-regulation of brain protein I3 (BRI3). Erk pathway was consequently
activated and led to the proliferation and migration of breast cancer cells.
Silencing BRI3 reversed the promoting effect of nifedipine on the breast cancer.
Materials and Methods
Cell culture and reagents
MCF-7 and MDA-MB-231 cells were purchased from Cell Library of Chinese
Academy of Sciences. MCF-7 were cultured in the DMEM medium(Promocell,
Germany) with 10% FBS (GIBCO, US) and maintained at 37 C˚ and in 5% CO2.
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MDA-MB-231 were grown in L-15 medium(Promocell, Germany) with 10%
FBSand maintained at 37 C˚ and in atmospheric air.
Nifedipine (Sigma), verapamil (Sigma), MTT (5 mg/ml, Sigma),
Paraformaldehyde (4%, Solarbio), Crystal violet (0.1%, Solarbio), RIPA
(Solarbio), PMSF (Solarbio), Cocktail (25x, Roche), Fura-8TM (AAT Bioquest),
DMSO (Sigma), CMC-Na (Beijing Chemical Technology, China), Nifedipine
Sustained-Release Tablets (Yangtze River Pharmaceutical Group, China),
Verapamil Hydrochloride Tablets (Central Pharmaceutical Co., Ltd, China).
Animal studies
Animal experiments conformed to the Guide for the Institutional Animal Care
and Use Committee (IACUC) and was approved by the Ethics Review Board for
Animal Studies of Institute of Molecular Medicine(IMM), Peking University
(Permit Number: IMM-GuYC-1). Balb/c nude mice were purchased from Vital
River (Beijing, China). Five to seven weeks old female nude mice were used for
tumor injections. MDA-MB-231 cells were infected by PsinDest5.1-GFP (a gift
from Professor YM Wang) to generate stable MDA-MB-231-GFP cells. 56106
MDA-MB-231-GFP breast cancer cells were suspended in 100ul cold D-PBS and
injected into the second fat pad of nude mice described as the previous report
[19]. One week after injection, when the breast tumor size reached 100mm3, nude
mice were then fed with nifedipine (4.8 mg/kg) (Yangtze River Pharmaceutical
Group), verapamil (4.8 mg/kg) (Central Pharmaceutical Co., Ltd, China) by
gauging. CMC-Na (Beijing Chemical Technology) and H2O were used as controls.
Nude mice were weighted every day and tumor size was measured every other day.
In vivo imaging of tumor metastasis
Tumor metastatic was monitored using invivo fluorescence. Nude mice were
anesthetized using isoflurane. The fluorescence was emitted from the tumors and
detected using a Kodak Imaging Systems (Kodak, New Haven, CT). Images were
digitally captured and overlaid onto the X-ray reference image (Kodak Imaging
System).
Proliferation assays
For determination of proliferation, MTT assay was used as reported previously.
Briefly, breast cancer cells were seeded at a density of 1,000 per well into 96-well
cell culture plates and allowed them to adhere for 24h. After incubation with
various concentration of nifedipine for 48h, 20 ml of MTT was added to each well
for 3h incubation. Subsequently, cells were dissolved by 150 mL of DMSO, mixed
and measured the absorbance (A) by Multiskan (Thermo) at 540nm. The relative
proliferation rate was calculated by the absorbance ratio of the nifedipine-treated
group to the control group.
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Cell migration assays
For transwell migration assays, harvested cells (16105 cells) supplement with
100ul of serum-free medium were replated onto the upper chamber (a 6.5-mm
polycarbonate membrane with 8.0-mm pores; Corning, NY) and the chamber was
placed in complete medium with 10% FBS and nifedipine. After 24hours, cells
were fixed with 4% paraformaldehyde in PBS. Non-migrated cells on the upper
side of the filter were removed with a cotton swab. Cells on the underside of the
filter were stained with 0.1% crystal violet for 20 minutes and then were eluted by
33% glacial acetic acid. OD values were read by Multiskan (Thermo) at 595nm.
Relative cell migration was determined by the OD values of nifedipine groups
normalized to the OD values of control groups.
Calcium imaging
Calcium imaging was performed by using Fura-8 TM (AAT Bioquest) according to
previous description. Fluorescence images of the cells were recorded and analyzed
with a video image analysis system.
Immunoblotting
Cells were lysed ice-cold RIPA lysis buffer (Solarbio) including PMSF and
proteinase inhibitor cocktail (Roche). Samples were centrifuged for 15min at
12000g at 4 C˚ and the supernatants were harvested. About 100 ug of each protein
sample were loaded and separated on 12% Bis-Tris Gel followed by transferring to
0.45 mm PVDF membrane. The membranes were then blocked with 5% non-fat
dry milk, probed with appropriate primary antibodies, followed incubation by
HRP-conjugated secondary antibodies at a dilution of 1: 3000. The following
antibodies were used: rabbit anti-P(Ser473)-Akt (Cell Signaling, #9271), rabbit
anti-total Akt (Cell Signaling, #9272), rabbit anti-P(Thr202/Tyr204)-Erk(Cell
Signaling, #9101), mouse anti-total Erk (cell signaling, #4696), mouse anti-
GAPDH (Beijing TDY Biotech LTD, #M010), mouse anti-b-actin (Beijing TDY
Biotech LTD, #M009), HRP-conjugated secondary mouse(Beijing TDY Biotech
LTD, #E009) and rabbit antibodies(Beijing TDY Biotech LTD, #E011).
Detection of mRNAs and miRNAs
Total RNA from cells and tumor tissue samples were extracted using Trizol
(Invitrogen). Chloroform was added to each sample and incubated for phase
separation. Samples were centrifuged at 12,000 g for 15min at 4 C˚ and the RNA
(top aqueous phase) was isolated. RNA was precipitated by mixing with
isopropanol gently and centrifuging at 12,000 g for 10min at 4 C˚. The RNA pellet
was washed with 75% ethanol, dried, and dissolved in RNase-free water.
For mRNAs detection and expression, total RNA was reverse transcribed using
random primers and cDNA synthesis Kit (TransGen Biotech). The resulting
Nifedipine Promotes Breast Cancer
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cDNAs were mixed with the SYBR PCR master mix (TransGen Biotech) and run
on the Step-One Plus Applied Biosystems Real-time PCR machine. One cycle of
denaturing step (30 sec at 94 C˚) was applied, followed by 40 cycles of
amplification (5 sec at 94 C˚ and 30sec at 60 C˚), with fluorescence measured
during the extension. 18s was as the house keeping gene to normalize the gene
expression. Primers used in this study are listed in the table S1.
For miRNAs detection, we employed All-in-OneTM miRNA qRT-PCR
Detection Kit (GeneCopoeia, #AOMD-Q020) according to the manufacturer’s
instructions. The U6 small nuclear RNA was used as the control to determine
relative miRNA expression.
The relative quantification value which reflected the fold changes of mRNAs/
miRNAs expression in nifedipine group compared to control was calculated using
the comparative CT (DDCT) method and StepOne
TM software v2.0.1 (Applied
Biosystems). At least three independent experiments were performed to derive
average relative quantification and SEM.
Gene expression microarray analysis
The aminoallyl-RNA (aRNA) probes were amplified using the MessageAmp
aRNA kit (Ambion, #1753) and labeled with the NHS-Cy5 (GE Amersham, USA,
#PA25001). The Cy5-labeled RNA probes were further purified and quantified.
The labeled probes were hybridized at 50 C˚ for 16hours to the Human Whole
Genome One Array TM Version 4.3(Phalanx Biotech Group, Taiwan) containing
30,968 well-characterized genes and then scanned with the Axon 4000B Scanner
(Molecular Devices, USA) as well as analyzed with Genepix software (Molecular
Devices USA).
Plasmids, oligonucleotides and transfection
For 39UTR reporter construction, the 39UTR of BRI3 were PCR-amplified from
human genomic DNA and cloned into the psiCHECK2 plasmid(Promega). The
plasmid sequences were verified to be free of mutation by direct sequencing. BRI3
si-RNA, hsa-miR-524-5p mimics were chemically synthesized and purified by
high-performance liquid chromatography (GenePharma, Shanghai, China). The
sequences targeted to silence BRI3 mRNA (NM_015379) were: 59-GAUUAAG-
CUUCAGGACUGUTT-39(sense), 59-ACAGUCCUGAAGCUUAAUCTT-39
(antisense). Hsa-miRNA-524-5p sequence were: 59-CUACAAAGGGAAG-
CACUUUCUC-39 (sense), 59-GAAAGUGCUUCCCUUUGUAGUU-39 (anti-
sense). Both mock and negative controls were used to assess the transfection.
Mock group was only transfected with Lipofectamine 2000(Invitrogen). Negative
control sequences: 59-UUCUCCGAACGUGUCACGUTT-39 (sense), 59-
ACGUGACACGUUCGGAGAATT-39 (antisense).
Nifedipine Promotes Breast Cancer
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Statistical analysis
The Student’s t-test was used for the statistical analysis of all the independent
experiments, with significance accepted at P,0.05. In the dependent experiments,
such as the tumor volume analysis, Mixed Model in SAS software was used. A p-
value of ,0.05 was considered statistically significant.
Results
Nifedipine stimulated the growth of breast cancer cell in the nude
mice
MDA-MB-231 breast cancer cells were transfected by PsinDest5.1-GFP to form
MDA-MB-231-GFP cells with stable fluorescence. To induce breast cancer invivo,
MDA-MB-231-GFP cells were injected into the second mamma fat pad (Fig. 1a).
After inoculated for one week, breast tumors in nude mice developed to 100mm3.
The tumor size was measured by vernier calipersize. Thereafter the nude mice
were treated with nifedipine by intra-gastric administration every day. The control
groups were fed with equivalent CMC-Na. As a result, after three weeks, the
tumor size in the nifedipine-treated group was significantly bigger than that in the
control groups (Fig. 1b), but there wasn’t significant alternation in the whole body
weight among different groups (Fig. 1e). Vivo imaging also showed that the
nifedipine-treated groups had stronger fluorescence than control after 3 weeks (
Fig. 1c i&ii), indicating that tumors in the nifedipine-treated group were more
active and invasive. Furthermore, a complete capsulewas predominantly observed
in the subcutaneous implanted tumor nodes of the CMC-Na groups by HE
staining of xenograft and no cancer cells observed outside the tumor node (Fig. 1d
i). In addition, there were large tumor cells necrosis and but little tumor cells
genesis (Fig. 1d iii). However, in nifedipine treated groups, tumor cells had
invaded into skeletal muscles (Fig. 1d ii), and tumor cells genesis along with
tumor cells necrosis was present (Fig. 1d iv). It was concluded that tumor grew
bigger and the fluorescence became stronger in the nifedipine-treated group after
two and four weeks (Fig. S1).
Nifedipine promoted proliferation and migration of breast cancer
cells invitro
To further investigate the effect of nifedipine on breast cancer cells, MDA-MB-231
breast cancer cells were treated with nifedipine at different concentrations invitro.
As measured by MTT assay, nifedipine significantly promoted the proliferation of
MDA-MB-231 cells and it induced the strongest proliferation at the concentration
of 1 mM (Fig. 2a). MDA-MB-231 cells also showed significant increased migration
in response to 1 uM nifedipine. The increased migration rate is nearly two fold of
the control (Fig. 2b).
In consistent with those findings, nifedipine exhibited the same effects on
another breast cancer cell line, MCF-7. Nifedipine also significantly promoted the
Nifedipine Promotes Breast Cancer
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Figure 1. The effect of nifedipine on the nude mice in vivo. a) Nude mice were injected with 5106 MDA-
MB-231-GFP cells into the second fat pads to imitate the orthotopic breast cancer inoculation. After one week
injection, when the breast tumor size reached 100mm3, nude mice were then fed with nifedipine (4.8 mg/kg)
or CMC-Na. b) The tumor volume in nude mice described in (a) was measured at the indicated time points and
plotted as the mean volume ¡ SEM; n510; P,0.01, Mixed Model in SAS software. c) In vivo imaging of
tumors treated with nifedipine or CMC-Na after three weeks(n510). i) Nifedipine groups had stronger
fluorescence compared with control groups. ‘NC’ represented negative control and it was used to eliminate
the background difference. ‘Control’ represented the mice treated with CMC-Na and ‘nifedipine’ represented
the mice treated with nifedipine. ii) The normalized photon flux showed that the fluorescence increased about
30%. n510; P,0.01,1-way ANOVA. d) HE staining of xenograft in subcutaneous implanted tumor models
after the treatment with nifedipine or CMC-Na. i) Control groups had complete envelope. Fewer cancer cells
invaded the envelope. ii) Nifedipine groups had uncompleted envelope and tumor cells invaded in skeletal
muscles. iii) Control groups had larger tumor cells necrosis and less tumor cells genesis. iv) Tumor cells
necrosis and genesis happened at the same time in nifedipine groups (Fig. i and ii magnification620; Fig. iii
and iv magnification640). e) Nifedipine has no effect the weight of nude mice. n510; P.0.05, Mixed Model
in SAS software.
doi:10.1371/journal.pone.0113649.g001
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proliferation and migration of MCF-7 cells at the concentration of 10 mM (Fig.
S2).
Verapamil, another CCBs, had no effect on the tumor growth
invivo
Nifedipine is one of the CCBs that are used to treat hypertension. To test whether
the stimulation of breast tumor is nifedipine specific, another CCBs, verapamil,
was used to treat nude mice infected with MDA-MB-231-GFP cells. However no
significant change in tumor size (Fig. 3a), tumor weight (Fig. 3b) and mice weight
(Fig. 3c) was observed. In addition, the fluorescence intensity exhibited no
difference between groups treated with nifedipine and CMC-Na (Fig. 3d). Thus
Figure 2. Nifedipine stimulated the survival and migration of breast cancer cells invitro. a) Different
concentrations of nifedipine could stimulate the proliferation of MDA-MB-231 cells. Results represented mean
¡ SEM of 3 independent experiments. P,0.01, 1-way ANOVA. b) Nifedipine (1 mM) promoted the migration
of MDA-MB-231 cells. Results represented the mean¡ SEM in 3 independent experiments. P50.003, 1-way
ANOVA.
doi:10.1371/journal.pone.0113649.g002
Nifedipine Promotes Breast Cancer
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Figure 3. Verapamil, another CCB, had no effect the tumor growth invivo. a) Verapamil had no obvious effect on tumor size in nude mice injected with
5?106 MDA-MB-231-GFP cells. Results represented the mean ¡ SEM. n510; P.0.05, Mixed Model in SAS software. b) Effect of different periods with
verapamil on the tumor weight. No obvious difference was observed. Results were represented the mean ¡ SEM. n510; P.0.05, 1-way ANOVA. c)
Verapamil had no effect on the weight of nude mice compared with the control. n510; P.0.05, Mixed Model in SAS software. d) In vivo imaging of the
tumors with the treatment of H2O and verapamil. i) Verapamil showed no effect on the tumor growth. ii) The normalized photon flux also showed no
difference between verapamil treated mice and control.
doi:10.1371/journal.pone.0113649.g003
Nifedipine Promotes Breast Cancer
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the specific effects of nifedipine on MDA-MB-231 cells were not a common
character of L-type calcium channel blockers.
Effect of nifedipine not due to intracellular Ca2+ in MDA-MB-231
cells
To test whether the effect of nifedipine on proliferation and migration of breast
cancer cells is related to the concentration of the intracellular free [Ca2+], the
MDA-MB-231 cells were preincubated in the presence of 1 mM nifedipine in L-15
containing 10% FBS for 1h at 37 C˚ and then loaded with Furo-8 as described in
‘‘Materials and Methods’’. No significant increase in [Ca2+]i was observed by
either nifedipine alone (Fig. 4a) or increasing the bath [K+] from 2.5 mM to
90mM (Fig. 4b), indicating that MDA-MB-231 cells didn’t express functional L-
type calcium channel. It suggested that effect of nifedipine on the proliferation
and migration of MDA-MB-231 cells was not related with calcium channel and
cellular [Ca2+].
Nifedipine activated signaling pathways to promote cell growth in
breast cancer cells
To elucidate the signaling pathways underlying the effects of nifedipine on breast
cancer cells, key factors involved in growth control of cancer cells were examined.
Strikingly, increase of phosphorylated Erk was found both in MDA-MB-231 cells
exposure to nifedipine (Fig. 5a) and in MDA-MB-231 tumor tissue from nude
mice treated with nifedipine (Fig. 5b).
Selection and validation of BRI3 as the candidate biomarkers
related to nifedipine
To find out the candidate targets of nifedipine regarding to its function on breast
cancer cells, tumor tissues from nude mice were used for gene expression analysis
by microarray (Fig. 6a). In tumor tissue gene expression of 51 genes was found
significantly up-regulated (Table. S2) and down-regulated in 18 genes (Table. S3).
Among them, there were 35 genes whose functions are related to cell adhesion and
migration (Table. S4) analyzed using DAVID (http://david.abcc.ncifcrf.gov/home.
jsp) for gene ontology annotation. Using real-time PCR, expression of 9 interested
genes was validated in the tumor tissues (Fig. 6b). Among them, 5 genes also had
the similar variation trend in MDA-MB-231 cells treated with nifedipine (Fig. 6c).
They included BRI3, SMOC1, KCNC4, PDE4DIP and COL14A1. To determine
the role of BRI3, SMOC1, KCNC4, PDE4DIP and COL14A1 in tumor
proliferation and migration, siRNAs were constructed to silencing the expression
of these genes in breast cancer cells. Silencing of BRI3 expression (Fig. 7a) could
markedly decrease the proliferation and migration (Fig. 7b, c) and suppress Erk
phosphorylation in MDA-MB-231 cell lines treated with nifedipine (Fig. 7d).
These results indicate that BRI3 is an important target related to the function of
nifedipine in the proliferation and migration of MDA-MB-231 breast cancer cells.
Nifedipine Promotes Breast Cancer
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We also confirmed that nifedipine could increase the expression of ANGPTL7
gene in the tumor [20] and MDA-MB-231 cells when treated with nifedipine for
48h compared with control (Fig. S3).
miRNA-524-5p acts as the upstream of BRI3 and indirectly
regulated BRI3
To seek the target miRNA of BRI3 we performed a TargetScan analysis and found
miR-524-5p, miR-1224-3p and miR-1229 as candidate target miRNA of BRI3
based on a TargetScan analysis (Fig. 8a). However only miR524-5-p was
eventually confirmed as a regulator of BRI3 as only the expression of miRNA-524-
5p decreased when MDA-MB-231 cells was treated with nifedipine for different
periods (Fig. 8b); but not the expression of miR-1224-3p and miR-1229 (data not
shown). Expression of miRNA-524-5p also decreased for nearly 2 folds in tumor
tissues from the nude mice (Fig. 8c). Furthermore overexpression of miRNA-524-
5p (Fig. 8d i) obviously decreased the expression of BRI3 gene (Fig. 8d ii), which
indicates miRNA-524-5p acting as upstream of BRI3. We inserted the 39UTR of
BRI3 gene to psiCHECK2 plasmid and tested the Renilla luciferase activity. As a
Figure 4. Effect of nifedipine on intracellular calcium concentration in MDA-MB-231 cells. (a) MDA-MB-
231 breast cancer cells were loaded with Furo-8 for 30 minutes, as described in ‘‘Materials and Methods’’.
Base-line [Ca2+]i was recorded, followed by sequential additions of 1 uM nifedipine. No obvious changes were
observed until the 150th picture was taken (n5300). (b) No significant increase in [Ca2+]i was observed by
increasing the bath [K+] from 2.5 mM to 90mM until the 150th picture was taken (n5300).
doi:10.1371/journal.pone.0113649.g004
Nifedipine Promotes Breast Cancer
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result, the Renilla/Firefly activity was no change by adding miRNA-524-5p mimics
(Fig. 8d iii). Overexpression of mi-RNA-524-5p also decreased the expression of
PDE4DIP, SMOC1 and COL14A1 (Fig. S4).
Figure 5. ERK activation in Nifedipine treated breast cancer cells. Phosphorylated Erk (P-Erk)
immunoblotting in MDA-MB-231 cells treated with or without nifedipine at the indicated times. The level of
phosphorylation was more intensive after treated with nifedipine for 40 minutes. Membranes were reprobed
for GADPH for loading control. Gray value was analyzed by the Image J software. Results were represented
the mean¡SEM. n53; 1-way ANOVA. b) Phosphorylated Erk (P-Erk) immunoblotting in tumor tissues from
nude mice treated with CMC-Na or nifedipine for 4 weeks. Membranes were reprobed for GADPH for loading
control. The results were consistent with that in the MDA-MB-231 cells.
doi:10.1371/journal.pone.0113649.g005
Nifedipine Promotes Breast Cancer
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Figure 6. Selection and validation of the candidate biomarkers related to nifedipine. a) Comparison of
gene expression profiles from nude mice tumors with the treatment of nifedipine or CMC-Na. Hierarchical
clustering of nude mice tumors with different treatments. A dendrogram of the tumors was shown at the top.
The changed genes were also clustered and gene names were on the right. Taken together, there were 51 up-
regulated and 18 down-regulated genes found. Among them, there were 35 genes related to cell adhesion
and migration. b) Transcript levels of differential genes in nude mice tumors treated with nifedipine or CMC-
Na. Nine genes (BRI3, SMOC1, LLGL1, KCNC4, TRIM3, ATP2C1, DLG1, PDE4DIP and COL14A1) were
found to have a consistent gain or loss in at least 10 tumor samples. The transcript levels were normalized to
the expression of internal 18s rDNA. Data were presented as the mean ¡ SEM of three independent
experiments. Specific comparison between nifedipine groups and control groups, P,0.01, 1-way ANOVA. c)
Transcript levels of differential genes in MDA-MB-231 cells treated with nifedipine for different periods by real-
time PCR. KCNC4, BRI3, SMOC1, PDE4DIP and COL14A1 genes were found to have a consistent gain or
loss in the MDA-MB-231 cells treated with nifedipine. Results were presented as the mean ¡ SEM of three
independent experiments. Specific comparison between nifedipine groups and control groups, **,P,0.01;
*, P,0.05,1-way ANOVA.
doi:10.1371/journal.pone.0113649.g006
Nifedipine Promotes Breast Cancer
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Discussion
In this study, we found that nifedipine significantly stimulated breast cancer
growth in the nude mice without any effects on the mice weight. In vivo imaging
of tumor tissue in nude mice showed that nifedipine treated mice had stronger
and wider range of fluorescence, suggesting tumors were more active and easier to
migrate. The pathological section confirmed the hypothesis. CMC-Na groups had
Figure 7. Inhibition of proliferation, migration and P-Erk of MDA-MB-231 by silencing BRI3 gene expression. a) Effective silencing of BRI3 mRNA in
MDA-MB-231 cells after siRNA treatment. BRI3-homo-584 siRNA markedly inhibited BRI3 mRNA expression at 100 nM after transfection for 24h. b) siRNA
directed against BRI3 suppressed the facilitation of nifedipine in the proliferation of MDA-MB-231 cells. Data were presented as the mean¡SEM of three
independent experiments. Specific comparison between nifedipine groups and control groups, P,0.01, 1-way ANOVA. c) MDA-MB-231 cells transfected
with mock, si-BRI3 and negative control were plated in the upper chamber of transwell. Data were presented as the mean ¡ SEM of three independent
experiments. Specific comparison between nifedipine groups and control groups, P,0.01, 1-way ANOVA. d) Increased protein expression of P-Erk in MDA-
MB-231 cell lines treated with nifedipine was inhibited 72h after transfection of BRI3-siRNA. M means mock, NC means negative control, SM-si means si-
SMOC1 gene, BR-si means si-BRI3 gene.
doi:10.1371/journal.pone.0113649.g007
Nifedipine Promotes Breast Cancer
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Figure 8. miRNA-524-5p was target of nifedipine and regulated the expression of BRI3. a) Predicted
duplex formation between human BRI3 39-UTR (top) and three miRNA (bottom) including has-miRNA-524-5p,
hsa-miR-1224-3p, hsa-miR-1229 by using TargetScan software. b) The expression of miRNA-524-5p
decreased in the MDA-MB-231 cells treated with nifedipine for different periods. Results were presented as
the mean¡SEM of three independent experiments. P,0.01, 1-way ANOVA. c) The expression of miRNA-
524-5p decreased in the tumor tissues from nude mice fed with nifedipine compared to CMC-Na groups.
Results were presented as the mean¡SEM of three independent experiments. P,0.05, 1-way ANOVA. d)
Overexpression of miRNA-524-5p could indirectly decrease the expression of BRI3 gene. i) MDA-MB-231
cells were transfected with miRNA-524-5p mimics and negative control (both 100 nM) for 24h. To test the
expression of miRNA-524-5p by qPCR and the expression of miRNA-524-5p increased about 8 times.
Results were presented as the mean¡SEM of three independent experiments. P,0.01, 1-way ANOVA. ii)
The expression of BRI3 gene decreased obviously compared with negative control when miRNA-524-5p
overexpressed. Results were presented as the mean¡SEM of three independent experiments. P,0.05, 1-
way ANOVA. iii) Relative luciferase activity (Renilla luciferase/Firefly luciferase) levels were measured after
24h from co-transfection of MDA-MB-231 cells with indicated BRI3-39UTR-psiCHECK2 plasmid with miRNA-
524-5p mimics or NC. The relative luciferase activity has no change. Results were presented as the
mean¡SEM of three independent experiments. P.0.05,1-way ANOVA.
doi:10.1371/journal.pone.0113649.g008
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complete envelopes and large tumor cells necrosis in the middle of tumors;
whereas cancer cells invaded skeletal muscles in the nifedipine treatment groups.
Additionally, nifedipine promoted the proliferation and migration of both MDA-
MB-231 and MCF-7 cells by in-vitro and in-vivo assay. However, verapamil,
another calcium channel blocker, didn’t have the similar effects in nude mice.
Previous studies have resulted in a controversial conclusion on whether CCBs
promote cancer cells. Our results confirmed that nifedipine can potentiate the
breast cancers. With respect to the possible mechanism, [Ca2+]i modulation was
excluded in the first instance. MDA-MB-231 cells don’t express the CACNA1C
and CACNA1D subtypes (data not shown), which is consistent with the previous
report [17]. Moreover, that 1 mM nifedipine failed to alter [Ca2+]i, ruled out the
connection between calcium and the promotion effect of nifedipine. The lack of
expression of voltage gated calcium channels (VGCCs) in breast cancer cells likely
counts upon the rationale that blockers of VGCCs should have no effect on breast
cancers. Inconsistent to most previous studies, nifedipine exerts the distinct effect
from verapamil, suggesting the specificity of nifedipine on its promotion outcome
instead of the character of general blockers of CCBs. Verapamil was even reported
to inhibit the growth of cancer cell [17]. Different compound structures and
binding motifs may explain the different effects of CCBs on cancer cells.
Nifedipine activated the phosphorylation of Erk in MDA-MB-231 cells both
invivo and invitro, which suggests it functions through Erk signaling pathway.
Referring to the target genes in the upstream of Erk, micro-array and Q-PCR
analysis from both invivo tumor tissues and invitro cancer cells consistently
reflected 9 interested genes. Among them, SMOC1, KCNC4, PDE4DIP and
COL14A1 have been reported to associate with a variety of tumors. SMOC1 is
SPARC (secreted protein, acidic and rich in cysteine) related modular calcium
binding 1[21, 22] and has been found a correlation with malignant progression,
such as brain tumor, colorectal cancer and breast cancer [23]. KCNC4 (potassium
voltage-gated channel, Shaw-related subfamily) is a potassium voltage-gated
channel and the expression increase of Kv3.4 can promote the proliferation of
OSCC [24]. PDE4DIP (also known as myomegalin, MMGL) is a tumor marker
for diagnose and establish a prognosis in patients with esophageal squamous cell
carcinoma [25]. COL14A1(collagenfamily) may be involved in the basement
membrane regulation, providing specific molecular bridges between fibrils and
other matrix components [26]. However, our work revealed that BRI3 is closely
related with this nifedipine effect on breast cancers. BRI3 participates in tumor
necrosis factor- induced cell death [26, 27]. Silencing of BRI3 expression clearly
suppressed the phosphorylation of Erk, and consequently the proliferation and
migration of MDA-MB-231 cells, suggesting that the BRI3-Erk signaling pathway
is involved in regulation of this nifedipine effect on breast cancers.
As another mechanism underlining nifedipine promoting the breast cancer cell
migration, up-regulation of ANGPTL7 was found in response to the nifedipine
treatment. ANGPTL7 is a member of angiopoietin family as vascular regulators
[20] which functions as a general endothelial cell survival factor [28] and
modulates endothelial cell adhesion [29]. Previous work has shown that ANGTL
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can cause the gap between endothelial cells resulting in the metastasis of breast
cancers [20].
MicroRNAs (miRNAs) are small, single-stranded, non-coding RNAs that
regulate gene expression[30]. Their dysregulation therefore contributes to cancer
cells’ proliferation and migration. For example, miRNA-10b initiated breast
tumor invasion and metastasis [31]. miRNA-135a promoted breast cancer cell
migration and invasion by targeting HOXA10 [32]. Restoration of miRNA-145
suppresses prostate cancer cell proliferation, migration and invasion by targeting
FSCN1 [33]. In our study, expression of miRNA-524-5p decreased after cells were
treated with nifedipine and miRNA-524-5p regulated the expression of BRI3 gene.
Thus the effects of nifedipine on breast cancer is carried out by miRNA-524-5p-
BRI3–Erk signaling pathway.
The women occupy about 1/3 in all the hypertension patients. Some of them
are suffering or are genetically easier to develop breast cancers. Thus it is urged
that prescription of nifedipine to women should be seriously caution. Nifedipine
is dangerous for patients with breast cancers and it may worsen the situation. As a
result, doctors should be aware of the fact that nifedipine promotes the breast
cancers and avoid nifedipine for the women especially who suffer both breast
cancer and hypertension.
Supporting Information
Figure S1. The effect of nifedipine on nude mice with different treatment time.
a) Nifedipine could increase the breast tumor volume and the facilitation was
more stronger at the 4 weeks than at 2 weeks. n510 in each group; Results
represented the mean¡SEM (standard error). P,0.01, Mixed model in SAS
software. b) Nifedipine could increase the breast tumor weight both in two weeks
and four weeks. n510 in each group; Results represented the mean¡SEM
(standard error). P,0.01, Mixed model in SAS software. c) In vivo imaging of the
tumors treated with nifedipine for different times. n510 in each group. i) As the
time went on, nifedipine groups had more stronger fluorescence than control
groups both in 2 weeks and 4 weeks. ii) The normalized photon flux showed the
results in figure. d) Nifedipine couldn’t effect the weight of nude mice compared
with the control groups at the 2 weeks or 4 weeks. n510 in each group; P.0.05,
Mixed model in SAS software. e) HE staining of xenograft in subcutaneous
implanted tumor models after the treatment with nifedipine or CMC-Na. Fig. i
and ii were from the tumors treated with CMC-Na or nifedipine for two weeks. i)
The envelope was complete in control groups and ii) it was becoming thin in
nifedipine groups. Fig. iii–vi were from tumors treated for 4 weeks. iii) The
envelope was thinner and v) more cells necrosis in control groups. iv) Meanwhile,
tumor cells invaded seriously in envelope and vi) less cancer cells necrosis in
nifedipine groups. (Fig. i,ii,v and vi magnification 610; Fig. iii and iv
magnification 620).
doi:10.1371/journal.pone.0113649.s001 (TIF)
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Figure S2. The effect of nifedipine on another breast cancer cell, MCF-7. a)
Nifedipine could promote the proliferation of MCF-7 cells at the concentration of
10 uM and the proliferation rate was about 10%. n532 per group; Results
represented mean¡SEM of 3 independent experiments. P,0.01,1-way ANOVA. b)
Nifedipine(10 uM) promoted the migration of MCF-7 cells. Results represented the
mean¡SEM in 3 independent experiments. P50.0008, 1-way ANOVA.
doi:10.1371/journal.pone.0113649.s002 (TIF)
Figure S3. The effect of nifedipine on the expression of ANGPTL7 gene. (A)
The expression of ANGPTL7 increased nearly 3 times in the tumor tissues from
nude mice treated with nifedipine. Results were presented as the mean¡SEM of
three independent experiments. *, P,0.05,1-way ANOVA. (B) The expression of
ANGPTL7 increased in the MDA-MB-231 cells treated with nifedipine for 48h.
Results were presented as the mean¡SEM of three independent experiments.
**, P,0.01,1-way ANOVA.
doi:10.1371/journal.pone.0113649.s003 (TIF)
Figure S4. miRNA-524-5p influenced the expression of other genes. (A)
Overexpression of miRNA-524-5p by adding the miRNA mimics also could
decrease the expression of other genes, such as PDE4DIP, SMOC1 and COL14A1.
Results were presented as the mean¡SEM of three independent experiments.
**, P,0.01,1-way ANOVA.
doi:10.1371/journal.pone.0113649.s004 (TIF)
Table S1. q-PCR primer list used in the study.
doi:10.1371/journal.pone.0113649.s005 (PDF)
Table S2. Up-regulated genes from nude mice tumors with the treatment of
nifedipine compared with CMC-Na.
doi:10.1371/journal.pone.0113649.s006 (PDF)
Table S3. Down-regulated genes from nude mice tumors with the treatment of
nifedipine compared with CMC-Na.
doi:10.1371/journal.pone.0113649.s007 (PDF)
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